Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学EGFR Exon 20 Insertion Lung Cancer

Suresh Ramalingam

MD

🏢Emory University🌐USA

Executive Director, Winship Cancer Institute

88
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Suresh Ramalingam leads Emory Winship Cancer Institute and has been instrumental in EGFR-targeted therapy development including exon 20 insertion trials. His work on osimertinib in earlier EGFR mutations provided the framework for exploring next-generation agents in uncommon variants. He co-chairs multiple national lung cancer cooperative group studies.

Share:

🧪Research Fields 研究领域

EGFR mutations
Exon 20 clinical trials
Thoracic oncology
Osimertinib
Combination regimens

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Suresh Ramalingam 的研究动态

Follow Suresh Ramalingam's research updates

留下邮箱,当我们发布与 Suresh Ramalingam(Emory University)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment